Study 10 Phase 1/2 trial

June 1, 2018June 6, 2018

European Commission Approves Clovis’ Rubraca for Recurrent Ovarian Cancer

News

The European Commission recently authorized Rubraca (rucaparib) for the treatment for women with recurrent BRCA-mutant ovarian cancer with relapsed or progressive disease. The recent approval is for the maintenance treatment of recurrent ... Read more

March 28, 2018

EU’s CHMP Supports Rubraca’s Approval for Advanced, Recurrent Ovarian Cancer

News

Rubraca (rucaparib) is a step closer to availability in Europe for ovarian cancer patients with relapsed or progressive disease. The E.U.’s Committee for Medicinal Products for Human Use (CHMP) recently ... Read more